EUVIMEDEUVIMED entdecken
Crossref

Synthesis of novel pyrimido[4,5‐ b ]quinolines as potential anticancer agents and HER2 inhibitors

Nahla Said M Ibrahim iD, Hanan H Kadry, Ashraf F Zaher, Khaled O Mohamed

Chemical Biology & Drug Design · 2023

DOI: 10.1111/cbdd.14307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Nahla Said M Ibrahim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Quinolines, Antineoplastic Agents, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Faculty of Pharmacy, Cairo University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of N ‐arylpyrimido[4,5‐ b ]quinolines 3a–e and 2‐aryl‐2,3‐dihydropyrimido[4,5‐ b ]quinoline‐4(1 H )‐ones 5a–e was designed and synthesized as potential anticancer agents against breast cancer. Compounds 3e , 5a, 5b , 5d, and 5e showed promising activity against the MCF‐7 cell line. Among them, compound 5b was the most active with IC 50 of 1.67 μM. Compound 5b promoted apoptosis and induced cell cycle arrest at S phase. 5b increased the level of pro‐apoptotic proteins p53, Bax, and caspase‐7 and inhibited the anti‐apoptotic protein Bcl‐2. Furthermore, all the synthesized compounds were docked into the crystal structure of HER2 (PBD: 3 pp0). Compounds 3e , 5a, 5b , 5d, and 5e showed good energy scores and binding modes. Finally, Compound 5b was evaluated on the HER2 assay and revealed good inhibition with IC 50 of 0.073 μM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesAntineoplastic AgentsErb-b2 Receptor Tyrosine KinasesHumansApoptosisMCF-7 CellsMolecular Docking SimulationStructure-Activity RelationshipProto-Oncogene Proteins c-bcl-2Drug Screening Assays, Antitumor

Stichwörter der Autor:innen

HER2MCF-7breast cancerpyrimido[4,5-b]quinolines

Substanzen

QuinolinesAntineoplastic AgentsErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanProto-Oncogene Proteins c-bcl-2

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

ORCID-Profile: Nahla Said M Ibrahim

Förderung

  • Faculty of Pharmacy, Cairo University

Zitieren

APA

Ibrahim, N. S. M., Kadry, H. H., Zaher, A. F., & Mohamed, K. O. (2023). Synthesis of novel pyrimido[4,5‐ b ]quinolines as potential anticancer agents and HER2 inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14307

Vancouver

Ibrahim NSM, Kadry HH, Zaher AF, Mohamed KO. Synthesis of novel pyrimido[4,5‐ b ]quinolines as potential anticancer agents and HER2 inhibitors. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14307

BibTeX
@article{Ibrahim2023,
  author = {Ibrahim, Nahla Said M and Kadry, Hanan H and Zaher, Ashraf F and Mohamed, Khaled O},
  title = {Synthesis of novel pyrimido[4,5‐ b ]quinolines as potential anticancer agents and HER2 inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  doi = {10.1111/cbdd.14307}
}
Kostenlos starten →